{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T04:02:28Z","timestamp":1770782548294,"version":"3.50.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"DOI":"10.3389\/fpsyt.2019.00767","type":"journal-article","created":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T15:49:19Z","timestamp":1572536959000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Patients With Drug-Naive Bipolar Disorder in Remission After 8 Weeks of Treatment Had Decreased Serum Uric Acid Concentrations"],"prefix":"10.3389","volume":"10","author":[{"given":"Jing-Xu","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Gang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke-Zhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Mei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang-Jiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Long","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shao-Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu-De","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu-Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,10,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2013.02.001","article-title":"Prevalence, chronicity, burden and borders of bipolar disorder","volume":"148","author":"Fagiolini","year":"2013","journal-title":"J Affect Disord"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00241-X","article-title":"Bipolar disorder","volume":"387","author":"Grande","year":"2016","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2004.00160.x","article-title":"GAMIAN-Europe\/BEAM survey II: cross-national analysis of unemployment, family history, treatment satisfaction and impact of the bipolar disorder on life style","volume":"6","author":"Morselli","year":"2004","journal-title":"Bipolar Disord"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200523060-00005","article-title":"Bipolar disorder and health-related quality of life: review of burden of disease and clinical trials","volume":"23","author":"Revicki","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/jcpp.12735","article-title":"Practitioner review: the effects of atypical antipsychotics and mood stabilisers in the treatment of depressive symptoms in paediatric bipolar disorder","volume":"58","author":"Atkin","year":"2017","journal-title":"J Child Psychol Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2012.01042.x","article-title":"Evidence-based options for treatment-resistant adult bipolar disorder patients","volume":"14","author":"Poon","year":"2012","journal-title":"Bipolar Disord"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0b013e32834b7c5f","article-title":"Psychotherapy for bipolar disorder: a review of the most recent studies","volume":"24","author":"Sch\u00f6ttle","year":"2011","journal-title":"Curr Opin Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2014.10.016","article-title":"Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics","volume":"57","author":"Ortiz","year":"2015","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0925-4927(01)00073-7","article-title":"Anatomical MRI study of basal ganglia in bipolar disorder patients","volume":"106","author":"Brambilla","year":"2001","journal-title":"Psychiatry Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.biopsycho.2012.01.008","article-title":"Structure-function associations in hippocampus in bipolar disorder","volume":"90","author":"Chepenik","year":"2012","journal-title":"Biol Psychol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/msj.20042","article-title":"Bipolar disorder: candidate drug targets","volume":"75","author":"Zarate","year":"2008","journal-title":"Mt Sinai J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2016.10.007","article-title":"Peripheral adenosine levels in euthymic patients with bipolar disorder","volume":"246","author":"Gubert","year":"2016","journal-title":"Psychiatry Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318268391d","article-title":"Purinergic system in the treatment of bipolar disorder: uric acid levels as a screening test in mania","volume":"32","author":"Machado-Vieira","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2605","article-title":"Purinergic signalling and disorders of the central nervous system","volume":"7","author":"Burnstock","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2010.12.001","article-title":"Adenosine receptors and brain diseases: neuroprotection and neurodegeneration","volume":"1808","author":"Gomes","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2016.03.014","article-title":"Exploring the association between bipolar disorder and uric acid: A mediation analysis","volume":"84","author":"Bartoli","year":"2016","journal-title":"J Psychosom Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12888-018-1952-z","article-title":"Association between hyperuricemia and metabolic syndrome in patients suffering from bipolar disorder","volume":"18","author":"Chen","year":"2018","journal-title":"BMC Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4274\/npa.y6827","article-title":"Are uric acid levels different from healthy subjects in bipolar affective disorder and schizophrenia?: relationship between clinical improvement and episode severity in male patients","volume":"51","author":"G\u00fcltekin","year":"2014","journal-title":"Noro Psikiyatr Ars"},{"key":"B19","article-title":"Increased uric acid levels in bipolar disorder: is it trait or state","volume":"27","author":"Kesebir","year":"2013","journal-title":"J Biol Regul Homeost Agents"},{"key":"B20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3389\/fpsyt.2018.00381","article-title":"Increased serum C3 and decreased UA in patients of bipolar disorder in chinese han population","volume":"9","author":"Yang","year":"2018","journal-title":"Front Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/mp.2017.188","article-title":"Purinergic system in psychiatric diseases","volume":"23","author":"Cheffer","year":"2018","journal-title":"Mol Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2174\/1871530319666190307165355","article-title":"Peripheral oxidative stress markers in patients with bipolar disorder during euthymia and siblings","author":"Tatay-Manteiga","year":"2019","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"B23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.eurpsy.2013.05.006","article-title":"Gender-based differences in oxidative stress parameters do not underlie the differences in mood disorders susceptibility between sexes","volume":"29","author":"Wiener","year":"2014","journal-title":"Eur Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2014.11.005","article-title":"Increased uric acid levels in bipolar disorder subjects during different phases of illness","volume":"173","author":"Albert","year":"2015","journal-title":"J Affect Disord"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2016.07.007","article-title":"Uric acid levels in subjects with bipolar disorder: a comparative meta-analysis","volume":"81","author":"Bartoli","year":"2016","journal-title":"J Psychiatr Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2018.04.030","article-title":"Serum uric acid levels in first episode mania, effect on clinical presentation and treatment response: data from a case control study","volume":"35","author":"Chatterjee","year":"2018","journal-title":"Asian J Psychiatr."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2014.05.013","article-title":"In a double-blind, randomized and placebo-controlled trial, adjuvant allopurinol improved symptoms of mania in in-patients suffering from bipolar disorder","volume":"24","author":"Jahangard","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0806","article-title":"A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania","volume":"69","author":"Machado-Vieira","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2012.01001.x","article-title":"Allopurinol augmentation in the outpatient treatment of bipolar mania: a pilot study","volume":"14","author":"Fan","year":"2012","journal-title":"Bipolar Disord"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12202","article-title":"Allopurinol for mania: a randomized trial of allopurinol versus placebo as add-on treatment to mood stabilizers and\/or antipsychotic agents in manic patients with bipolar disorder","volume":"16","author":"Weiser","year":"2014","journal-title":"Bipolar Disord"},{"key":"B31","article-title":"Diagnostic and statistical manual of mental disorders","year":"1994"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12717","article-title":"Is there consensus across international evidence-based guidelines for the management of bipolar disorder","volume":"135","author":"Parker","year":"2017","journal-title":"Acta Psychiatr Scand"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br J Psychiatry."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800320058007","article-title":"A structured interview guide for the Hamilton Depression Rating Scale","volume":"45","author":"Williams","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/pcn.12518","article-title":"Purinergic dysfunction in bipolar disorder: Any role for the antioxidant uric acid as a trait and state biomarker","volume":"71","author":"Bartoli","year":"2017","journal-title":"Psychiatry Clin Neurosci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2017.1270758","article-title":"Convergent lines of evidence support the role of uric acid levels as a potential biomarker in bipolar disorder","volume":"17","author":"Machado-Vieira","year":"2017","journal-title":"Expert Rev Mol Diagn"},{"key":"B37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1586\/ern.12.149","article-title":"Is there a clinical prodrome of bipolar disorder","volume":"13","author":"Martin","year":"2013","journal-title":"A review of the evidence. Expert Rev Neurother"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.02.027","article-title":"Increased uric acid levels in drug-naive subjects with bipolar disorder during a first manic episode","volume":"34","author":"Salvadore","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2015.07.047","article-title":"Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: results from the FACE-SZ cohort","volume":"168","author":"Godin","year":"2015","journal-title":"Schizophr Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.05.009","article-title":"Serum uric acid and mortality in chronic kidney disease: a systematic review and meta-analysis","volume":"65","author":"Xia","year":"2016","journal-title":"Metabolism"},{"key":"B41","first-page":"195","article-title":"Evaluation of plasma antioxidant levels during different phases of illness in adult patients with bipolar disorder","volume":"22","author":"De Berardis","year":"2008","journal-title":"J Biol Regul Homeost Agents."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2014.11.038","article-title":"Serum uric acid levels and different phases of illness in bipolar I patients treated with lithium","volume":"225","author":"De Berardis","year":"2015","journal-title":"Psychiatry Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1176\/ajp.156.1.129","article-title":"Prethymoleptic use of lithium","volume":"156","author":"El-Mallakh","year":"1999","journal-title":"Am J Psychiatry"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(91)90070-V","article-title":"Plasma uric acid in patients receiving anticonvulsant monotherapy","volume":"8","author":"Ring","year":"1991","journal-title":"Epilepsy Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2010.02066.x","article-title":"A single-blind, comparative study of zotepine versus haloperidol in combination with a mood stabilizer for patients with moderate-to-severe mania","volume":"64","author":"Chan","year":"2010","journal-title":"Psychiatry Clin Neurosci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31829e8168","article-title":"An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation","volume":"33","author":"Chan","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.06111932","article-title":"Olanzapine versus placebo in the treatment of adolescents with bipolar mania","volume":"164","author":"Tohen","year":"2007","journal-title":"Am J Psychiatry"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n1113","article-title":"Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study","volume":"69","author":"Tohen","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.115.180281","article-title":"Allopurinol as add-on treatment for mania symptoms in bipolar disorder: systematic review and meta-analysis of randomised controlled trials","volume":"210","author":"Bartoli","year":"2017","journal-title":"Br J Psychiatry."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.30773\/pi.2016.12.31","article-title":"The relationship between the number of manic episodes and oxidative stress indicators in bipolar disorder","volume":"15","author":"Akarsu","year":"2018","journal-title":"Psychiatry Investig"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5049\/EBP.2014.12.1.1","article-title":"Uric acid puzzle: dual role as anti-oxidantand pro-oxidant","volume":"12","author":"Kang","year":"2014","journal-title":"Electrolyte Blood Press"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BSR20170939","article-title":"Uric acid promotes oxidative stress and enhances vascular endothelial cell apoptosis in rats with middle cerebral artery occlusion","volume":"38","author":"Song","year":"2018","journal-title":"Biosci Rep"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-010-0195-2","article-title":"Role of oxidative stress in the pathophysiology of bipolar disorder","volume":"35","author":"Steckert","year":"2010","journal-title":"Neurochem Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2014.04.053","article-title":"Uric acid levels may be a biological marker for the differentiation of unipolar and bipolar disorder: the role of affective temperament","volume":"165","author":"Kesebir","year":"2014","journal-title":"J Affect Disord"},{"key":"B55","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1176\/appi.ps.201200143","article-title":"Cigarette smoking among persons with schizophrenia or bipolar disorder in routine clinical settings, 1999-2011","volume":"64","author":"Dickerson","year":"2013","journal-title":"Psychiatr Serv"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s12199-010-0198-2","article-title":"Effect of cigarette smoking on plasma uric acid concentrations","volume":"16","author":"Haj Mouhamed","year":"2011","journal-title":"Environ Health Prev Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar1906","article-title":"A concise history of gout and hyperuricemia and their treatment","volume":"8","author":"Nuki","year":"2006","journal-title":"Arthritis Res Ther"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpsyt.2019.00767\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T15:49:21Z","timestamp":1572536961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpsyt.2019.00767\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,31]]},"references-count":57,"alternative-id":["10.3389\/fpsyt.2019.00767"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2019.00767","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,31]]},"article-number":"767"}}